ストックスクリーナーアプリを入手
9.13
1.90%
0.17
アフターアワーズ：
9.13
前日終値:
$8.96
開ける：
$9.09
24時間の取引高:
582.04K
Relative Volume:
1.77
時価総額：
$615.07M
収益：
$568.09M
当期純損益:
$27.27M
株価収益率:
27.87
EPS:
0.3276
ネットキャッシュフロー:
$71.41M
1週間 パフォーマンス:
-0.22%
1か月 パフォーマンス:
+3.99%
6か月 パフォーマンス:
+36.47%
1年 パフォーマンス:
-0.22%
1日の値動き範囲:
$8.64
$9.38
1週間の範囲:
$8.64
$9.39
52週間の値動き範囲:
$5.81
$9.56
Bioventus Inc Stock (BVS) Company Profile
名前
Bioventus Inc
セクター
電話
(919) 474-6700
住所
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.13 | 603.62M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | 開始されました | CJS Securities | Market Outperform |
| 2026-02-09 | 開始されました | Barrington Research | Outperform |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-07 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | アップグレード | Craig Hallum | Hold → Buy |
| 2022-11-22 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-11-09 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 開始されました | Craig Hallum | Buy |
| 2021-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2021-11-10 | 再開されました | JP Morgan | Overweight |
| 2021-07-01 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-08 | 開始されました | Canaccord Genuity | Buy |
| 2021-03-08 | 開始されました | Goldman | Buy |
| 2021-03-08 | 開始されました | JP Morgan | Overweight |
| 2021-03-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioventus Inc (BVS) 最新ニュース
Surprises Report: Is Bioventus Inc in a bullish channel2026 Gainers & Daily Technical Stock Forecast Reports - baoquankhu1.vn
BVS PE Ratio & Valuation, Is BVS Overvalued - intellectia.ai
CJS Securities Initiates Coverage on Bioventus (NASDAQ:BVS) - Defense World
BVS Technical Analysis & ETF Price Forecast - intellectia.ai
Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan
(BVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Bioventus Inc.(NasdaqGS: BVS) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
BVS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Aug Wrap: Does Bioventus Inc offer margin of safetyEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Barrington Research initiates coverage of Bioventus (BVS) with outperform recommendation - MSN
Does Bioventus Inc have a competitive edge2026 Buyback Activity & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan
Travel Stocks: Is Bioventus Inc attractive for institutional investors2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Bioventus : Corporate PresentationMarch 2026 - marketscreener.com
Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat
Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus
Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat
Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan
Bioventus Receives Consensus Buy Rating from Analysts - National Today
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - MSN
Bioventus stock delivers 63% return after Fair Value signal By Investing.com - Investing.com Australia
Bioventus stock delivers 63% return after Fair Value signal - Investing.com India
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
BVS (NASDAQ: BVS) files Form 144 for 12,000 Class A shares via Fidelity - Stock Titan
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
BVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com India
Barrington Adjusts Price Target on Bioventus to $14 From $13, Maintains Outperform Rating - marketscreener.com
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus Q4 Earnings Assessment - Sahm
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) 財務データ
収益
当期純利益
現金流量
EPS
Bioventus Inc (BVS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Singleton Mark Leonard | SVP & CFO |
Mar 13 '26 |
Option Exercise |
0.00 |
13,500 |
0 |
165,312 |
| CHURCH KATRINA J | SVP & Chief Compliance Officer |
Mar 13 '26 |
Option Exercise |
0.00 |
6,955 |
0 |
63,253 |
| D'Adamio Anthony | SVP & General Counsel |
Mar 13 '26 |
Option Exercise |
0.00 |
17,636 |
0 |
151,844 |
| Claypoole Robert E | President and CEO |
Mar 13 '26 |
Option Exercise |
0.00 |
33,500 |
0 |
150,497 |
| McMurry-Heath Michelle | Director |
Mar 11 '26 |
Sale |
8.79 |
12,000 |
105,439 |
44,997 |
2.03%
大文字化:
|
ボリューム (24 時間):